Kim Mi-Jung, Gong Gyungyub, Joo Hee Jae, Ahn Se-Hyun, Ro Jae Y
Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Arch Pathol Lab Med. 2005 Oct;129(10):1277-82. doi: 10.5858/2005-129-1277-IACCOI.
A micropapillary carcinoma (MC) component is generally considered to behave aggressively. Although several reports have described the prognostic significance of MC in breast carcinomas, immunohistochemical findings of MC, especially as compared to non-MC, are rarely described.
We compared clinicopathologic and immunohistochemical findings between 38 cases of invasive breast carcinoma with an MC component (IMC) and 217 cases of invasive breast carcinoma without an MC component (NIMC).
We constructed a tissue microarray from 38 cases of IMC and performed immunohistochemical stainings for cytokeratin (CK) 7, CK20, estrogen receptor, progesterone receptor, p53, c-Erb-B2, CD34, CK5, epidermal growth factor receptor, and c-Kit in both MC and non-MC components.
Cases with IMC were associated with greater tumor size, more frequent lymphovascular invasion, nodal metastases, greater mean numbers of positive lymph nodes, and higher stage than those with NIMC, but were not associated with poorer survival rates. On immunohistochemistry, only p53 reactivity was statistically different between MC and non-MC components in IMC cases. Estrogen receptor positivity tended to be lower in MC than non-MC, but the difference was not significant. Most of the MCs and non-MCs in IMC cases were positive for CK7, but none of them were positive for CK20, CK5, epidermal growth factor receptor, or c-Kit.
Based on the frequent nodal metastases and association with higher stage found in IMC as compared with NIMC cases, as well as higher p53 positivity and lower frequency of estrogen receptor expression, MC could be considered an aggressive histologic type of breast carcinoma. In both MC and non-MC components in IMC cases, no basallike immunostaining pattern was detected.
微乳头癌(MC)成分通常被认为具有侵袭性。尽管有几份报告描述了MC在乳腺癌中的预后意义,但很少描述MC的免疫组化结果,尤其是与非MC相比。
我们比较了38例伴有MC成分的浸润性乳腺癌(IMC)和217例不伴有MC成分的浸润性乳腺癌(NIMC)的临床病理和免疫组化结果。
我们从38例IMC病例构建了组织芯片,并对MC和非MC成分进行细胞角蛋白(CK)7、CK20、雌激素受体、孕激素受体、p53、c-Erb-B2、CD34、CK5、表皮生长因子受体和c-Kit的免疫组化染色。
与NIMC病例相比,IMC病例的肿瘤更大,淋巴管侵犯、淋巴结转移更频繁,阳性淋巴结的平均数量更多,分期更高,但生存率并无差异。免疫组化显示,在IMC病例中,仅p53反应性在MC和非MC成分之间存在统计学差异。MC中的雌激素受体阳性率往往低于非MC,但差异不显著。IMC病例中的大多数MC和非MC对CK7呈阳性,但对CK20、CK5、表皮生长因子受体或c-Kit均无阳性。
基于与NIMC病例相比,IMC中频繁的淋巴结转移和更高分期的相关性,以及更高的p53阳性率和更低的雌激素受体表达频率,MC可被认为是一种侵袭性组织学类型的乳腺癌。在IMC病例的MC和非MC成分中,均未检测到基底样免疫染色模式。